Emster Kurt von - 31 Jul 2026 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: Director
Issuer ticker: JSPR
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 16:10:32 UTC
Prior SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Herb Cross, as Attorney-in-Fact

Key filing fact

Emster Kurt von filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 04 Aug 2026.

Key facts

This page summarizes Emster Kurt von's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001252524 Primary reporting owner

EMSTER KURT VON

Relationship: Director
Address: C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PKWY, SUITE #102, REDWOOD CITY
Signature: /s/ Herb Cross, as Attorney-in-Fact
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Stock Option (Right to Buy

Award

Transaction value
Shares: +7,500
Change %
Price: $0.000000^*
Shares after: 7,500
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 7,500
Exercise price: $0.6300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.